| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b7ac4c39167cc78f276a5e6088babed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff476bb2370dc7f6275a189bff922097
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90bdd3287688eb3c00e3b10a6877fb97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd7e2d3813c2c5d4b4782657b3ddd39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf4ae3c2c3f0ded6a5670c515121fd8f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2005-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5030754791f728066baaa97f9cfece26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea0a930d526f018d9002d54207992773
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a605f9cf9a8fe1e54b6662a7fbc73a0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a503b9342e35a1ee849edbab5646dc6c |
| publicationDate |
2012-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8158362-B2 |
| titleOfInvention |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
| abstract |
Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10080748-B2 |
| priorityDate |
2005-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |